Final answer:
The FDA regulatory endpoint for bioengineered foods that are not substantially different from their non-engineered counterparts is a determination of 'No concerns', allowing these GMOs to be marketed without further petitions. Scientific consensus from various authoritative organizations underlines the safety of genetically engineered crops, with ongoing studies focused on potential allergenic effects.
Step-by-step explanation:
The regulatory endpoint after the FDA's assessment of bioengineered foods, when a GMO is approved for marketing because it is not substantially different in composition from the non-engineered counterpart, is a determination of 'No concerns'.
This means that the GMO can be marketed without the need for a food additive petition. The rationale behind this regulatory outcome is grounded in a broad scientific consensus which confirms the safety of genetically engineered (GE) crops. The FDA, along with various scientific bodies such as the UN's Food and Agriculture Organization, the National Academies of Sciences, Engineering, and Medicine (NASEM), and the American Medical Association, have concluded that the risks to human and animal health from the use of GMOs are negligible.
These authoritative bodies support that there is no substantiated evidence of health risks between commercial GE crops and conventionally bred crops. It is important to note that potential allergenic effects of GE crops continue to be a subject of study. Nevertheless, because traditional breeding can also introduce new genetic traits, it is considered wise to continue studying all new crop varieties for potential risks to human health.